+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the efficacy and safety of three different dose levels of SRSD107 compared to enoxaparin 40 mg daily in adults aged 60 to 80 undergoing elective primary unilateral total knee arthroplasty TKA. This Phase 2, multicenter, randomized, open-label study includes a blinded endpoint evaluation and aims to find the best dose of SRSD107 for preventing venous thromboembolism VTE after surgery. Participants will be assigned to one of four groups low, medium, or high single subcutaneous doses of SRSD107, or enoxaparin 40 mg subcutaneously once daily for 12 2 days after surgery. The identity of the study drug is known, but the specific SRSD107 dose is blinded. Up to approximately 450 subjects will be randomized to these groups. During the study, participants will take the study drug at least 28 days before surgery and attend clinic visits, including venography 10 to 14 days after TKA. Researchers will monitor the incidence of total VTE events from surgery through 12 2 days post-surgery as the primary outcome. Secondary outcomes include major VTE, bleeding events, and adverse events up to Day 169. Safety and efficacy assessments will continue throughout the study period, which ends in October 2026.

Age: 60Years - 80YearsAll GendersPhase 2
1 location
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations